CoChat
Sign Up
Cited by 210Treatment of Major DepressionChild and Adolescent Psychosocial and Emotional DevelopmentAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Escitalopram in the Treatment of Adolescent Depression: A Randomized Placebo-Controlled Multisite Trial

Open access
Emslie, Graham J., Ventura, Daniel, Korotzer, Andrew, Tourkodimitris, Stavros·2009·Journal of the American Academy of Child & Adolescent Psychiatry
DOI 10.1097/chi.0b013e3181a2b304
Open this paper in CoChat — free accountOpen PDF

Abstract

Objective This article presents the results from a prospective, randomized, double-blind, placebo-controlled trial of escitalopram in adolescent patients with major depressive disorder. Method Male and female adolescents (aged 12-17 years) with DSM-IV-defined major depressive disorder were randomly assigned to 8 weeks of double-blind treatment with escitalopram 10 to 20 mg/day (n = 155) or placebo (n = 157). The primary efficacy parameter was change from baseline to week 8 in Children's Depression Rating Scale-Revised (CDRS-R) score using the last observation carried forward approach. Results A total of 83% patients (259/312) completed 8 weeks of double-blind treatment. Mean CDRS-R score at baseline was 57.6 for escitalopram and 56.0 for placebo. Significant improvement was seen in the escitalopram group relative to the placebo group at endpoint in CDRS-R score (-22.1 versus -18.8, p =.022; last observation carried forward). Adverse events occurring in at least 10% of escitalopram patients were headache, menstrual cramps, insomnia, and nausea; only influenza-like symptoms occurred in at least 5% of escitalopram patients and at least twice the incidence of placebo (7.1% versus 3.2%). Discontinuation rates due to adverse events were 2.6% for escitalopram and 0.6% for placebo. Serious adverse events were reported by 2.6% and 1.3% of escitalopram and placebo patients, respectively, and incidence of suicidality was similar for both groups. Conclusions In this study, escitalopram was effective and well tolerated in the treatment of depressed adolescents.

Overview

Integrity signals

Registry

Crossref · 10.1097/chi.0b013e3181a2b304

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 23 references

Cited by

Sorted by citations

Items 101–200 of 209

Related

See all

Metadata

Authors
Emslie, G. J., Ventura, D., Korotzer, A., & Tourkodimitris, S.
Affiliations
The University of Texas Southwestern Medical Center (US)
Corresponding author
Emslie, Graham J.
ORCID
Emslie, Graham J.
Venue
Journal of the American Academy of Child & Adolescent Psychiatry
Publisher
Elsevier BV
Published
2009-07
Volume
48
Issue
7
Pages
721-729
ISSN
0890-8567 (ISSN-L)
DOI
10.1097/chi.0b013e3181a2b304
OpenAlex
W2003027810
Cited by
210
References
23
Citations by year
2026: 10 · 2025: 12 · 2024: 14 · 2023: 12 · 2022: 17 · 2021: 12 · 2020: 10 · 2019: 16 · 2018: 11 · 2017: 9 · 2016: 11 · 2015: 5 · 2014: 9 · 2013: 17 · 2012: 16
FWCI
10.29
Type
journal article
Language
en
Open access
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Journal of the American Academy of Child & Adolescent Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Psychology › Clinical Psychology › Child and Adolescent Psychosocial and Emotional Development
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Keywords
escitalopram, adolescent depression, major depressive disorder, selective serotonin reuptake inhibitors, antidepressant efficacy, drug tolerability, adverse events, suicidality, Children's Depression Rating Scale-Revised
MeSH terms
Adolescent, Child, Major Depressive Disorder, Double-Blind Method, Female, Humans, Male, Patient Dropouts, Personality Assessment, Prospective Studies, Psychometrics, Citalopram, Adverse Drug Reaction Reporting Systems, Antidepressive Agents, Second-Generation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review